Genprex enters research agreement with the University of Pittsburgh

Genprex (GNPX) announced that following the recent completion of its two-year Sponsored Research Agreement with the University of Pittsburgh of the Commonwealth System of Higher Education to study Type 1 diabetes and Type 2 diabetes, the parties have entered into a new SRA to study GPX-002, the company’s gene therapy for diabetes, in T1D and T2D in animal models. Genprex has entered into a new SRA with Pitt in which the Company will sponsor preclinical studies of GPX-002 for the treatment of T1D and T2D in animal models. Preclinical data from an animal study of GPX-002 in T1D showed statistically significant decreases in insulin requirements, increases in c-peptide levels and improvements in glucose tolerance in the treated animals compared to baseline. These groundbreaking results support the hypothesis that this disruptive gene therapy approach developed by Pitt researchers may be a promising treatment for both T1D and T2D.